- Lexaria’s DehydraTECH™ drug delivery platform promotes healthier ingestion methods
- The company continues to leverage its technology in new areas
- Lexaria was recently granted new Australian patents and new notices of allowance
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a leader in enhancing the flavor, bouquet and gastro-intestinal delivery of edible cannabinoid consumer products. It has patents granted in the U.S. and Australia for applications of its DehydraTECH™ technology. Moreover, the company has many patents pending in over 40 nations. Lexaria Bioscience’s business strategy involves expanding the applicability of its technology within and beyond the cannabinoid sector. Recently upgraded to the OTC Markets’ OTCQX Best Market, Lexaria Bioscience is based in Kelowna, British Columbia.
The DehydraTECH™ drug delivery platform promotes healthier ingestion methods. It considerably improves the body’s ability to absorb cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, nicotine, drugs, supplements and other valuable molecules. The platform boosts the performance of useful compounds in ingestible products across the taste, smell, speed of action, bioabsorption and bioavailability categories.
The DehydraTECH™ drug delivery platform eliminates the unwanted taste in cannabinoid edibles. It also boosts bioabsorption by five to 10 times and lessens time of onset. The effects are felt within 15 to 20 minutes. Essentially, the DehydraTECH™ technology enables the transportation of bioactive substances via oral ingestion and does so without the need for inhalational dosing. It is more effective than traditional ingestion and avoids the dangers associated with smoking. Lexaria developed and out-licenses its DehydraTECH™ drug delivery platform.
Lexaria was recently granted three new patents by the Australian Patent Office (http://cnw.fm/1DlnZ). Lexaria Bioscience is the only company with patents issued for oral delivery of all cannabinoids. The new Australian patents bring Lexaria’s international patent portfolio to eight issued patents, including four in the U.S. and Australia, respectively.
In addition, the U.S. Patent & Trademark Office (USPTO) issued two new notices of allowance for pending patent applications. Lexaria expects to receive corresponding U.S.-issued patents before the end of this year. The company has filed more than 50 patent applications across nine current patent families.
The DehydraTECH™ drug delivery platform patents name a wide spectrum of lipophilic bioactives and food carrier/particles, which can be formulated and delivered using the company’s technology. The patents include method and composition of matter claims. The USPTO issued the first patent in October 2016. In February 2017, the first international patent was accepted for issuance in Australia (http://cnw.fm/8xtJm).
Lexaria is continuing to leverage its technology in new areas. For example, the DehydraTECH™ drug delivery platform could allow nicotine to be ingested orally. While the company has not yet partnered with the tobacco industry, its strategy includes disruptive nicotine delivery methods (http://cnw.fm/t8gR5). It remains to be seen if a nicotine industry partnership might evolve. DehydraTECH™ has been shown to deliver nicotine to the brain quicker than traditional delivery methods. Lexaria Biosciences’ strength is its commitment to using its innovative technology to open up new avenues of growth in diverse markets.
For more information, visit the company’s website at www.LexariaBioscience.com
More from CanadianCannabisWire
About CanadianCannabisWire
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.canadiancannabiswire.com
Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
CanadianCannabisWire (CNW)
Toronto, Ontario
www.canadiancannabiswire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com
